Literature DB >> 34153201

The Supine Superior Semicircular Canal Dehiscence Test.

Carrie W Hoppes1, Karen H Lambert2, Chris Zalewski3, Robin Pinto4, Holly Burrows4, Devin McCaslin5.   

Abstract

Purpose The purpose of this clinical focus article is to describe a new method for assessment of superior semicircular canal dehiscence by laying the patient supine during Valsalva-induced nystagmus testing. Method The traditional Valsalva-induced nystagmus test is described, followed by a new method for assessment of superior semicircular dehiscence conducted by laying the patient supine during testing. A case study is presented to illustrate this new testing technique known as the Supine Superior Semicircular Canal Dehiscence Test. Results It is hypothesized that during Valsalva-induced nystagmus testing performed in the upright, seated position, the dura mater could potentially seal the superior semicircular canal fistula, thereby concealing a defect in the bony labyrinth and yielding a false-negative test. To circumvent this, the patient should be placed in the supine position during Valsalva-induced nystagmus testing in order to prevent the dura mater from inadvertently sealing itself against the petrous portion of the temporal bone. The Supine Superior Semicircular Canal Dehiscence Test may reveal the defect in the bony labyrinth and improve the sensitivity of the Valsalva-induced nystagmus test. Conclusions The Supine Superior Semicircular Canal Dehiscence Test may be more sensitive for identifying superior semicircular canal dehiscence in patients with traditional symptoms and a negative Valsalva-induced nystagmus test in the seated position. While a case study is presented to illustrate the potential benefits of including the Supine Superior Semicircular Canal Dehiscence Test in the battery of diagnostic tests, further research is needed in larger samples.

Entities:  

Mesh:

Year:  2021        PMID: 34153201      PMCID: PMC8642096          DOI: 10.1044/2021_AJA-21-00011

Source DB:  PubMed          Journal:  Am J Audiol        ISSN: 1059-0889            Impact factor:   1.636


  20 in total

1.  Symptoms, findings and treatment in patients with dehiscence of the superior semicircular canal.

Authors:  K Brantberg; J Bergenius; L Mendel; H Witt; A Tribukait; J Ygge
Journal:  Acta Otolaryngol       Date:  2001-01       Impact factor: 1.494

2.  Superior canal dehiscence syndrome.

Authors:  L B Minor
Journal:  Am J Otol       Date:  2000-01

Review 3.  General vestibular testing.

Authors:  Thomas Brandt; Michael Strupp
Journal:  Clin Neurophysiol       Date:  2005-02       Impact factor: 3.708

4.  The effect of electrode positioning on the ocular vestibular evoked myogenic potential to air-conducted sound.

Authors:  Jaswinder S Sandhu; Stefan R George; Peter A Rea
Journal:  Clin Neurophysiol       Date:  2013-01-18       Impact factor: 3.708

5.  Symptoms and signs in superior canal dehiscence syndrome.

Authors:  L B Minor; P D Cremer; J P Carey; C C Della Santina; S O Streubel; N Weg
Journal:  Ann N Y Acad Sci       Date:  2001-10       Impact factor: 5.691

6.  The development of the Dizziness Handicap Inventory.

Authors:  G P Jacobson; C W Newman
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1990-04

7.  Do signs of natural plugging of superior semicircular canal dehiscence exist?

Authors:  Cristina Brandolini; Giovanni Carlo Modugno
Journal:  Am J Otolaryngol       Date:  2011-08-15       Impact factor: 1.808

8.  Improvement in autophony symptoms after superior canal dehiscence repair.

Authors:  Benjamin T Crane; Frank R Lin; Lloyd B Minor; John P Carey
Journal:  Otol Neurotol       Date:  2010-01       Impact factor: 2.311

Review 9.  Superior Canal Dehiscence Syndrome: Lessons from the First 20 Years.

Authors:  Bryan K Ward; John P Carey; Lloyd B Minor
Journal:  Front Neurol       Date:  2017-04-28       Impact factor: 4.003

10.  A Tool to Quantify the Functional Impact of Oscillopsia.

Authors:  Eric R Anson; Yoav Gimmon; Tim Kiemel; John J Jeka; John P Carey
Journal:  Front Neurol       Date:  2018-03-15       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.